Bonnie Fletcher Price

Cooley successfully defeated a patent infringement suit for its client Vifor (International) AG, a pioneer in iron deficiency and anemia therapies. The Cooley IP litigation team representing Vifor was led by intellectual property (IP) litigation partners Sanya Sukduang and Jonathan Davies, with support from cyber/data/privacy partner Tiana Demas and IP litigation associates John Habibi and Bonnie Fletcher Price.

Cooley represented Sight Sciences (listed as SGHT on Nasdaq), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, which received a jury trial win on April 26, 2024, against its competitors – Alcon, Alcon Vision and Alcon Research (collectively known as Alcon) and Ivantis – in the US District Court for the District of Delaware.

Cooley is representing NeuroDerm and its parent company, Mitsubishi Tanabe Pharma Corp., in a post-grant review challenging an AbbVie patent related to methods of continuous subcutaneous treatment of Parkinson’s disease. After a hearing in October 2023, the US Patent Trial and Appeal Board issued a final written decision finding all claims of AbbVie’s patent unpatentable.

NeuroDerm and AbbVie are both seeking regulatory approval in the US for continuous subcutaneous treatments for Parkinson’s disease, and AbbVie’s patent effectively attempted to claim all successful methods of such treatment. Lawyers Geoff Biegler and Mark Weinstein are leading the team representing NeuroDerm with assistance from associates, Bonnie Fletcher Price and Andrew Lau.